



Multimeric Biotherapeutics, Inc.
("MultimericBio")
"Unlocking the potential of the TNF SuperFamily Ligands"

Multimeric Biotherapeutics selected to present at BIOCOM Investor Conference

Aug. 24, 2009, San Diego, CA – Multimeric Biotherapeutics, Inc. was selected to present at the 4th Annual BIOCOM Investor Conference to be held on Oct. 26 – 27, 2009 at the Hyatt Regency in La Jolla, CA. This two day conference will highlight investments opportunities in Southern California's top life science companies to over 500 of the nation's top institutional investors.

Thirty-nine of the presenting companies are in the area of therapeutics. Of these, 16 are publicly traded on the NASDAQ. This makes MultimericBio one of the youngest companies selected to present. Marc Hertz, Ph.D., the CEO of MultimericBio, will give a 25 minute presentation scheduled for Monday, October 26th at 10:30 AM. Over 400 attendees are expected, which include some of the top investors and biotech executives in the United States.

For further details, visit http://www.biocom.org/event/2009_Investor_Conference/

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is a biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at www.multimericbio.com . Contact us at info@multimericbio.com